US pharma pay-for-delay deals could live to fight another day
This article was originally published in SRA
Executive Summary
If the US Supreme Court decides that reverse-settlement agreements between innovator drug makers and generic firms are violations of law, then patents and intellectual property rights would be devalued, with patent holders and challengers left spending time and resources fighting litigation to judgment – a losing scenario for everybody, insisted Washington lawyer Diane Bieri, a partner at Arnold and Porter.